Shop in your local currency and language

Choose another country or region to see specific content for your location and shop online.

United Kingdom
Process development

Decentralizing cell therapy manufacturing without losing control

Aug 27, 2026

Distance remains one of the most significant barriers to delivering autologous cell therapies at scale. Patients may need to travel long distances to receive treatment, while starting material and finished therapies depend on long, tightly controlled logistics chains to connect manufacturing sites with patient centers (1).

Although the core manufacturing process may take as little as 10 days, real‑world vein‑to‑vein timelines can stretch into months once scheduling, transportation, and release processes are factored in. Each handoff compounds cost, risk, and—most critically—time.

For patients with rapidly progressing diseases, these timelines can be decisive. As Dharmesh Vara, Leader of Cell Therapy Field Application Specialists in the UK, observes:

“Patients are having major issues accessing healthcare. In the centralized model, you have a few manufacturing sites distributing to a limited number of centers across different countries and reaching these locations becomes extremely difficult for patients.”

Decentralized manufacturing offers a patient-centric alternative—bringing production closer to the point of care to reduce the logistical burden and expand access.

The challenge? Maintaining centralized process control across a distributed network.

This article explores how decentralized manufacturing could democratize patient access to autologous cell therapies, and the operational and digital foundations required to make it feasible without losing operational control.

What decentralized manufacturing really means for cell therapy

Europe has emerged as an early testing ground for decentralized manufacturing of autologous cell therapies, enabled in part by regulatory frameworks that allow access to Advanced Therapeutic and Medicinal Products (ATMPs) prepared on a non-routine, patient-specific basis.

The Hospital Clínic Barcelona in Spain has treated over 500 patients with its academic CAR T cell therapy, manufactured on-site. Operating under a point-of-care (PoC) model and the EU hospital exemption pathway, over 13 partnered hospitals across the country are qualified to refer patients, perform leukapheresis, and administer the final dose (2).

More recently, PoC regulations introduced in the UK pave the way for a more fully decentralized approach (3). This framework allows manufacturing at local ‘spoke’ sites embedded within patient care centers, while a central ‘hub’ retains responsibility for materials, process oversight, data aggregation, and product release.

This ‘hub-and-spoke’ model is designed to enable scalable, GMP-grade manufacturing of personalized therapies across dozens or even hundreds of sites, including those outside major metropolitan areas.

As Vara explains:

“It’s all about access to healthcare. By creating local networks, we can give patients a lifeline—treatment options closer to home, and potentially at lower cost.”

The objective is replication: the same process, performed the same way, every time, regardless of site, operator, or geography. Manufacturing must remain standardized, traceable, and auditable across the entire network.

Achieving that level of control and coordination across people, processes, equipment, and data is the central challenge manufacturers must solve to make decentralization work in the real world.

What it takes to maintain control across decentralized operations

Decentralized manufacturing cannot rely on manual coordination alone. To maintain control across sites, manufacturers require a foundation that standardizes execution, connects operations, and enforces consistency at scale.

Such a foundation consists of three key capabilities:

Standardizing processes across sites

In a decentralized model, quality is no longer limited to a single facility. Consistency must be designed into the process itself to prevent site‑to‑site variability.

In practice, this requires alignment across three core aspects:

  • Process control: identical workflows and SOPs, ensuring every site performs the same validated process, every time
  • Material control: coordinated sourcing and use of GMP-enabling raw materials and consumables
  • Execution control: consistent training, guidance, and deviation management across teams

Automated, closed systems play a critical role in standardization of these aspects by reducing manual intervention and limiting operator-derived variability. In parallel, centralized sourcing, qualification, and inventory strategies help maintain comparability while simplifying network oversight.

Enforcing centralized oversight and documentation

A major risk of decentralized manufacturing is process drift between sites. Centralized oversight is essential to prevent divergence on how each location manages documentation, deviations, and release.

Traditional paper‑based documentation quickly becomes operationally unstable in a decentralized context, especially as scale grows.

As Vara recalls from a workshop with UK manufacturers:

“In some cases, a single batch manufacturing record can be up to 2000 pages—all of which must be reviewed for final product release. If you only have a few patients a year, that might be manageable, but as you increase the number of patients coming through, that paper burden becomes unrealistic.”

A viable decentralized model therefore depends on a digital manufacturing infrastructure capable of:

  • Standardizing and distributing controlled processes and operating procedures across all sites
  • Capturing manufacturing data in real time
  • Enabling remote monitoring, review, and release

These capabilities would enable quality teams to manage decentralized manufacturing as a single, unified operation, rather than a collection of independent sites.

Meeting regulatory expectations at scale

Decentralized manufacturing is new territory for ATMPs, which can make the regulatory landscape of cell and gene therapy manufacturing feel even more complex.

As Sandra Racordon-Pape, Director of Regulatory Science and Strategy, explains, regulatory frameworks for decentralized manufacturing are still emerging globally, but flexibility for ATMPs is generally increasing (see: FDA’s new flexible CMC framework for CGT).

That flexibility comes with a tradeoff: a greater burden of proof. Manufacturers must demonstrate that processes remain consistent, controlled, and fully documented, regardless of where production takes place.

In other words, decentralized operations must prove they can function as a single, unified manufacturing system, meeting the same GMP standards expected of centralized facilities.

Racordon-Pape highlighted several key areas of regulatory focus:

Product consistency across sites

To mitigate risk of process parameter drift, regulators expect robust comparability strategies, including:

  • Side-by-side batch comparisons across sites
  • Clearly defined critical quality attributes (CQAs)
  • Consistent execution of defined process controls (e.g., through automation)

These strategies must be backed up by data such as validated analytical assays, as well as stability and analytical comparability studies.

Importantly, regulatory bodies increasingly expect strong process understanding. Manufacturers must be able to scientifically justify process parameters and demonstrate control over them.

Centralized control across the network

Evidence of centralized oversight that enforces process control and consistency across sites includes:

  • Standardized and centrally governed processes
  • Harmonized documentation and deviation management practices
  • Coordinated change control across all locations

The human component is equally important. Variability in training, execution, or deviation handling, particularly in Corrective and Preventive Action (CAPA) processes, can quickly lead to divergence if not centrally aligned.

Chain of identity and traceability

Manufacturers must demonstrate end-to-end traceability of patient material, without risk of mix-ups or misidentification. This requires:

  • Integrated tracking of materials, samples, and products across sites
  • Complete, accurate, and accessible batch documentation
  • Systems capable of linking a batch to every step of the manufacturing process

Disconnected or manual systems introduce significant risks in all three areas, making a coordinated, system-level approach essential to realizing decentralized manufacturing of cell therapies.

Building a digital and automated foundation

The above expectations for cell therapy manufacturing aren’t entirely new, but rather amplifications of existing ones. Processes that are already complex in a single facility must now be coordinated across multiple sites and teams.

Manufacturing execution systems (MES) already play a central role in enforcing process control, documentation, and compliance in many centralized facilities. A decentralized model needs the same capabilities to extend seamlessly across distributed operations.

When combined, manufacturing execution systems, automation, and closed systems provide the foundation for coordinating and standardizing operations across decentralized sites:

  • Digital platforms standardize processes, capture data, and enable centralized oversight
  • Automated systems reinforce consistent execution and reduce operator variability
  • Closed manufacturing supports GMP compliance, reduces risk of contamination, and lowers infrastructure burden

These technologies shift control from local execution to a centrally governed, system-driven model and enabling decentralized manufacturing to operate as a unified process.

A practical infrastructure for decentralized manufacturing

MES platforms like Chronicle™ software are designed to provide the level of control needed for decentralized operations: connecting manufacturing sites, standardizing execution, and automating batch documentation so that separate activities can function as a single, coordinated system.

Chronicle™ software creates this digital infrastructure by enabling:

  • Central deployment of processes, including eSOPs, parameter sets, and applications, ensuring identical execution across all locations
  • Synchronized deployment of parameter groups and software updates onto connected equipment
  • Integrated materials management, supporting use of identical process inputs
  • Guided digital workflows, reducing operator variability and minimizing manual steps such as transcription and calculations
  • Embedded system checks, flagging potential deviations such as expired materials (products and consumables), incorrect consumable type, or out-of-maintenance equipment

Together, these capabilities support a highly controlled, system-driven process that supports reproducibility regardless of site or operator.

Learn more about features that reinforce standard operation and reduce batch failure risk

Enabling real-time visibility, monitoring, and release

Maintaining control across decentralized sites requires continuous visibility into operations.

Chronicle™ software enables manufacturing to be monitored and managed as a unified operation through:

  • Live visibility into manufacturing activities across sites
  • Real-time monitoring of instrument data during expansion, including temperature and CO2
  • Generation of electronic manufacturing batch records (eMBRs), consolidating process data, operator actions, and events into structured, reviewable records
  • Integrated deviation workflows, enabling rapid identification, investigation, and resolution of issues
  • Remote review and release capabilities, allowing quality teams to assess batches without being physically present at each site

By aggregating data across instruments and sites, Chronicle™ enables continuous, remote oversight by centralized quality and operations teams. This capability reduces the need for specialized personnel at each site without sacrificing a high level of control.

Compared to paper-based systems, digital records also enable progressive review during execution, rather than retrospective review at the end of the process—helping reduce documentation bottlenecks and accelerate time to release.

Executing standardized processes at the point of care

Digital control may be the foundation of decentralized operations, but it can only succeed when supported by equipment that can precisely execute procedure steps, support real-time monitoring, and integrate seamlessly into a centralized digital environment.

Systems such as the Sefia™ cell therapy manufacturing platform are designed to operate as connected nodes within the Chronicle™ ecosystem, linking execution with centralized oversight.

Lowering the barrier to GMP compliance

Decentralized manufacturing is best enabled by systems that can operate inside hospitals and clinics without requiring extensive facility upgrades.

The Sefia™ cell therapy manufacturing platform is designed to enable GMP-compliant execution from apheresis processing to final dose formulation, featuring:

  • Functionally closed workflows, enabling compliant manufacturing in lower‑grade cleanroom environments
  • Sterile, single‑use consumables, reducing contamination risk and enabling rapid batch turnover
  • GAMP 5 Category 3 systems and software, supporting fast setup and validation

As connected nodes, Sefia™ systems generate structured manufacturing data that feeds directly into Chronicle™ software, enabling centralized monitoring and review across the network.

Explore the full CAR T manufacturing workflow with the Sefia™ platform

Balancing standardization and process flexibility

While decentralization requires strict process consistency, manufacturing systems must also be flexible enough to support development and optimization needs of multiple therapeutics and allow a smooth transition to GMP manufacturing.

The Sefia™ platform balances both requirements:

  • Extensive configurability during development, with hundreds of adjustable parameters to support optimization
  • Role‑based parameter locking in GMP manufacturing, ensuring standardized execution across all sites

This approach allows processes to be defined and refined centrally, then deployed and executed uniformly across a distributed network.

Read our app note on Sefia™ platform compatibility with several commercial serum-free media and membrane materials

Scaling capacity within decentralized sites

As treatable indications grow, decentralized hubs may need to deliver hundreds of doses annually, often within limited clinical space.

Modular manufacturing platforms like Sefia™ systems are designed to maximize productivity within space-constrained environments:

  • Parallel batch processing, increasing throughput within a small footprint
  • Targeted capacity expansion, allowing sites to add specific modules as needed without duplicating hardware or overinvesting in all-in-one unit operations

This modularity supports a more capital-efficient scale-up model ideal for decentralized hubs operating within hospitals and patient centers.

Learn more about the advantages of modular manufacturing

Supporting flexible scheduling with cryopreservation

Patient readiness and manufacturing capacity rarely align perfectly. Cryopreservation provides flexibility without adding operational complexity.

The VIA Freeze™ and VIA Thaw™ systems extend control and standardization to these critical upstream and downstream steps by:

  • Standardizing freezing and thawing processes
  • Reducing contamination risk compared to water baths through controlled, closed procedures
  • Ensuring full traceability, with all data captured within Chronicle™ software

Read more about best practices for cryopreservation and optimized cell thawing strategies.

Decentralized manufacturing depends on centralized control

In practice, decentralized manufacturing is less about where manufacturing happens, and more about how processes, data, and decisions are managed when manufacturing is no longer confined to a single location.

While it’s likely that a combination of centralized and decentralized operations will ultimately best support patient access to cell and gene therapies, it’s safe to say that automated, closed, and digitally connected systems will be essential to delivering consistent, high-quality therapies regardless of location.

Vara sees massive potential in the decentralized approach:

“Manufacturing could be at hospitals, but it could also be a mobile unit. In the future, it could even be at specialized outpatient pharmacies that bring essential healthcare closer to patients.”

With the right foundation, that potential is well within reach.

References
  1. KPMG. The USD 30K CAR‑T therapy: a future within reach?. KPMG. Published 2025. Accessed June 18, 2026.
  2. Hospital Clinic Barcelona. Hospital Clinic‑IDIBAPS, pioneer in CAR T‑cell therapies for cancer with over 500 patients treated. Hospital Clinic Barcelona. Published April 2, 2025. Accessed June 18, 2026.
  3. Medicines & Healthcare products Regulatory Agency. Human medicines: modular manufacture and point of care regulations 2025 overview. GOV.UK. Published June 10, 2025. Accessed June 18, 2026.
Explore modular manufacturing solutions
Whether you’re building a centralized or decentralized cell therapy manufacturing, modular manufacturing enables aglity, cost efficiency, and a clear path to scale.

Did you find what you were looking for?